Shijia Lu | Medicine | Best Researcher Award

Posted on by Pencis

Mr. Shijia Lu | Medicine | Best Researcher Award

Sanquan College of Xinxiang Medical University | China

AUTHOR PROFILE

ORCID ID

🏥MR. SHIJIA LU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Mr. Shijia Lu embarked on his academic journey with a Bachelor’s degree in Biotechnology from Sanquan College of Xinxiang Medical University. Demonstrating early interest in tumor-targeted therapy, he quickly advanced into translational research and academic publishing. His undergraduate years were marked by robust interdisciplinary learning, laying the foundation for integrating bioinformatics, network pharmacology, and molecular simulations in cancer research.

🩺PROFESSIONAL ENDEAVORS

Currently serving as the Associate Editor of Guide to Biomedical Research Tools, Mr. Lu also holds student membership in the Chinese Society for Biotechnology. His roles extend beyond editorial to include project leadership, drug discovery, and computational biology. He has successfully led and contributed to university-level and provincial scientific projects, focusing on innovative strategies to combat cancer resistance.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON MEDICINE

Mr. Lu’s research is centered on tumor-targeted therapies, especially those overcoming PCNA-mediated resistance. Notable among his contributions:

  • Invented the “Structural Coupling – Functional Synergy” strategy, bridging natural product EGCG and synthetic inhibitors for synergistic effects.

  • Designed AL-1/AL-3, novel dual-ligand inhibitors tackling L47V mutation resistance in cancer cells.

  • Engaged in multi-omics-driven screening for anti-cancer components in natural sources such as pomegranate peel.
    His integrative research style blends wet-lab validation with computational simulations (AutoDock Vina, Cytoscape, ESM-Fold), setting a new paradigm in anti-cancer drug design.

🌍IMPACT AND INFLUENCE

Lu’s research has received national-level recognition, influencing the development of next-generation PCNA inhibitors. His PCNA-targeted strategy, featured in In Silico Research in Biomedicine, provides a blueprint for multi-target drug designs. Through editorial and competition platforms, he has advocated bioinformatics integration in biomedical research, inspiring peer groups and junior researchers in China’s academic circuits.

🏆 ACCOLADES AND RECOGNITION

Awards:
🥈 Second Prize, National College Students’ Innovation and Entrepreneurship Competition (Medical Health Category)
🏅 Three national-level research competition awards
🌍 Two provincial-level foreign language translation awards

🏆LEGACY AND FUTURE CONTRIBUTIONS

Mr. Lu’s pioneering research in drug resistance mechanisms, particularly in PCNA-targeted therapy, promises long-term value to precision oncology. His interdisciplinary approach—linking structural biology, network pharmacology, and bioinformatics—will likely influence future drug discovery pipelines, especially for hard-to-treat tumors. He is poised to emerge as a thought leader in the next generation of biomedical researchers.

🧬CONCLUSION

With a dynamic blend of technical mastery, scientific curiosity, and a vision for impact, Mr. Shijia Lu is a rising biomedical innovator. His work addresses one of the greatest challenges in medicine today—anti-cancer drug resistance—while his leadership in academia and publishing continues to foster new frontiers in biotechnology and translational research.

📊🔬NOTABLE PUBLICATION:

Design and anti-drug resistance research of novel PCNA-targeted inhibitors based on network pharmacology and molecular docking

Authors: Shijia Lu; YiRan Zhen; Jinwen Sima; Jinle Wang; Qihao Zhu; Miaoyan Han; Mengdan Sang; Xuejiao Li; Bing Zhang; Zihan Wang; et al.

Journal: In Silico Research in Biomedicine

Year: 2025

Rui Liu | Tumor Radiobiology | Best Researcher Award

Posted on by Pencis

Dr. Rui Liu | Tumor Radiobiology | Best Researcher Award

Wenzhou Medical University | China

AUTHOR PROFILE

SCOPUS ID

GOOGLE SCHOLAR

🏥DR. RUI LIU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Rui Liu began her academic journey with a strong foundation in biomedical sciences, eventually earning a Ph.D. from a prestigious institution renowned for excellence in public health and molecular oncology. Her early research experiences centered on cellular biology and radiation mechanisms, which laid the groundwork for her specialization in tumor radiobiology and DNA damage repair (DDR).

🩺PROFESSIONAL ENDEAVORS

Currently serving as a Lecturer at the School of Public Health, Wenzhou Medical University, Dr. Liu has dedicated herself to cutting-edge cancer research. With over five years of hands-on laboratory experience, she has developed deep expertise in molecular biology, gene editing (CRISPR-Cas9), animal modeling, bioinformatics, and cellular imaging technologies. Her academic career reflects a balance between rigorous research and impactful teaching, mentoring the next generation of oncology researchers.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR RADIOBIOLOGY

Dr. Liu’s core research explores the molecular intricacies of radiotherapy resistance, with a focus on DNA damage repair pathways and ferroptosis in tumor cells. She has pioneered studies that unravel how long non-coding RNAs (lncRNAs) like MALAT1 influence cancer cell radiosensitivity, potentially leading to enhanced radiotherapy strategies. Her work contributes valuable insights into overcoming therapeutic resistance in breast cancer and other solid tumors.

🌍IMPACT AND INFLUENCE

Dr. Liu’s research has significantly advanced understanding in her field, evidenced by 445+ citations, an H-index of 12, and impactful publications in SCI-indexed journals. She is an active voice in the scientific community, engaging in collaborative research with Jilin University and contributing to national and provincial projects. Her affiliations with professional societies amplify her influence in radiological toxicology and environmental biophysics.

🏆 ACCOLADES AND RECOGNITION

Notable Awards:

  • 🎓 National Scholarship for Doctoral Excellence

  • 🌟 Recognition as a promising young investigator in radiobiology

🏆LEGACY AND FUTURE CONTRIBUTIONS

As an emerging leader in radiation oncology research, Dr. Liu aims to translate molecular findings into clinical applications that improve therapeutic outcomes. She mentors student researchers and continues to expand her interdisciplinary work on novel radiotherapy biomarkers, synthetic lethality, and non-coding RNA therapeutics. Her commitment ensures sustained contributions to precision oncology and translational cancer science.

🧬CONCLUSION

Dr. Rui Liu exemplifies the next generation of scientists transforming cancer treatment through molecular radiobiology. With a robust publication record, interdisciplinary collaborations, and active academic service, she is poised to leave a lasting impact on oncology research, education, and clinical innovation. Her ongoing efforts promise to redefine therapeutic strategies for radiation-resistant cancers.

📊🔬NOTABLE PUBLICATION:

Title: Metal ions overloading and cell death
Authors: Y. Lai, F. Gao, R. Ge, R. Liu, S. Ma, X. Liu
Journal: Cell Biology and Toxicology
Year: 2024

Title: Post‐translational modifications of protein in response to ionizing radiation
Authors: X. Liu, R. Liu, Y. Bai, H. Jiang, X. Fu, S. Ma
Journal: Cell Biochemistry and Function
Year: 2020

Title: The comparison of epidemiological characteristics between confirmed and clinically diagnosed cases with COVID-19 during the early epidemic in Wuhan, China
Authors: F. Shi, H. Wen, R. Liu, J. Bai, F. Wang, S. Mubarik, X. Liu, Y. Yu, Q. Hong, J. Cao, …
Journal: Global Health Research and Policy
Year: 2021

Title: Association between single nucleotide variants of vascular endothelial growth factor A and the risk of thyroid carcinoma and nodular goiter in a Han Chinese population
Authors: R. Liu, L. Ning, X. Liu, H. Zhang, Y. Yu, S. Zhang, W. Rao, J. Shi, H. Sun, Q. Yu
Journal: Oncotarget
Year: 2017

Title: The challenges of precision radiotherapy technology to the traditional theory of radiobiology
Authors: S. Ma, Z. Liang, Q. Chen, R. Liu, Y. Guo, X. Liu
Journal: Chinese Journal of Radiological Medicine and Protection
Year: 2019

Title: Tumor-associated macrophages in radiotherapy: Mechanisms of polarization, immune regulation and therapeutic strategies
Authors: S. Ma, Z. Liang, X. Liu, R. Liu
Journal: Frontiers in Oncology
Year: 2023

Xinglu Jiang | Drug Delivery | Best Researcher Award

Posted on by Pencis

Assoc. Prof. Dr. Xinglu Jiang | Drug Delivery | Best Researcher Award

Guangxi Medical University College | China

AUTHOR PROFILE

SCOPUS ID

ORCID

🏥DR. XINGLU JIANG: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Jiang Xinglu earned his Doctor of Medicine from the Medical School of Southeast University, one of China’s premier medical institutions. His academic focus was in clinical laboratory diagnostics, and he was awarded for outstanding doctoral dissertation, reflecting early excellence in translational medical research.

🩺PROFESSIONAL ENDEAVORS

Currently serving as Associate Professor and Director of the Experimental Research Department at the School of Stomatology, Guangxi Medical University, Dr. Jiang leads advanced research in biomaterials and oral disease diagnostics. He is also recognized among the Outstanding Talents among Youth of Guangxi, marking him as a key figure in the next generation of Chinese medical scientists.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON DRUG DELIVERY

Dr. Jiang’s core research lies at the intersection of biomaterials, nanotechnology, and oral disease therapy. His major interests include:

  • Intelligent anti-tumor drug delivery systems

  • Antibacterial biomaterials

  • Stimuli-responsive hydrogels and nanocarriers

  • Innovative PCR-based diagnostic techniques

  • Carrier-free multidrug therapy systems

His innovative work in tumor microenvironment-triggered nanomedicine and qPCR amplification correction methods represents significant progress in precision medicine and diagnostics.

🌍IMPACT AND INFLUENCE

Dr. Jiang’s research has contributed to:

  • The development of visual antimicrobial hydrogels with regenerative capacity in dental therapy.

  • Advanced PCR technologies for accurate genetic quantification.

  • Carrier-free nanodrug systems for trimodal therapy, combining chemo, photothermal, and starvation treatments for cancer.

These contributions have clinical translational potential in both oncology and dental medicine, influencing practice and technology development in China and internationally.

🏆 ACADEMIC CITES, ACCOLADES AND RECOGNITION

  • Nearly 30 SCI-indexed publications, with over 10 as first or corresponding author.

  • Published in top-tier journals including:

    • ACS Nano

    • Analytical Chemistry (AC)

    • Chemical Engineering Journal (CEJ)

    • Theranostics

    • Journal of Controlled Release (JCR)

    • Analytica Chimica Acta (ACA)

  • Recognized for exceptional publication quality and multidisciplinary innovation.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Dr. Jiang is poised to lead next-generation research in:

  • Smart biomaterials for real-time diagnostic feedback

  • Multifunctional nanoplatforms for targeted therapy

  • Standard-free absolute quantification methods in clinical genetics

He is also an advocate for translational research, mentoring emerging scientists and contributing to the future of stomatology and biomedical engineering.

🧬CONCLUSION

Dr. Jiang Xinglu exemplifies the modern medical scientist — innovative, interdisciplinary, and impact-driven. Through cutting-edge contributions in drug delivery systems, oral disease treatment, and clinical diagnostics, he is reshaping the interface between nanomedicine and clinical practice. His trajectory suggests continued breakthroughs, especially in precision therapy and regenerative oral medicine.

📊🔬NOTABLE PUBLICATION:

Sunlight-enhancing the destruction of biomacromolecules caused by Au and Pb ions through cycling between Au(0) and Au(III)

  • Authors: Jiang Xinglu, Qin Yiwu, Zhou Jun, … , Zhou Fengyuan

  • Journal: Colloids and Surfaces A: Physicochemical and Engineering Aspects

  • Year: 2025

Three birds with one stone: a facile superparamagnetic aptasensor for selective capture, dual-mode detection and efficient elimination of methicillin-resistant Staphylococcus aureus

  • Authors: Zhao Fengfeng, Yao Yuming, Ma Shuo, … , Jiang Xinglu, Wu Guoqiu

  • Journal: Chemical Engineering Journal

  • Year: 2025

Visual Antimicrobial Gold Nanocluster Hydrogel with Inflammation-Responsive and Time-Regulated Swelling/Degradation for Regenerative Endodontic Procedures

  • Authors: Xie Beibei, Liang Chunyun, Liu Cong, … , Wang Yaling, Jiang Xinglu

  • Journal: ACS Nano

  • Year: 2025

Ping Dai | Cancer Therapy | Best Researcher Award

Posted on by Pencis

Dr. Ping Dai | Cancer Therapy | Best Researcher Award

Tongji University | China

AUTHOR PROFILE

SCOPUS ID

🏥DR. PING DAI: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Ping Dai’s journey in medicine began with a Diploma of Higher Education in Clinical Medicine from Harbin University, followed by a Bachelor’s degree at Qiqihar Medical University. She excelled further with an Outstanding Master’s Degree in Oncology from Shihezi University, and culminated her academic path with a Doctorate in Molecular Radiation Oncology (Dr. Med, Magna Cum Laude) from the prestigious Heidelberg University in Germany—underscoring a profound commitment to academic excellence and clinical innovation.

🩺PROFESSIONAL ENDEAVORS

With over a decade of clinical and research experience, Dr. Dai currently serves as Assistant Director at the Shanghai Fourth People’s Hospital Affiliated to Tongji University. Her career spans multiple critical roles—oncologist, clinical researcher, and international doctoral candidate at the German Cancer Research Centre (DKFZ)—fusing global perspectives with localized healthcare innovation.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON BIOMARKERS  IN CANCER THERAPY

Dr. Dai’s research centers on radiation oncology, immunotherapy-related thyroid dysfunction, and tumor treating fields (TTFields). Notably, her recent studies explore PD-1/PD-L1 inhibitor-induced thyroid dysfunction as a biomarker for efficacy in advanced lung cancer therapy, published in BMC Cancer and Heliyon. She also leads groundbreaking simulation research on electrodynamic tumor interactions, merging clinical oncology with bioengineering insight.

🌍IMPACT AND INFLUENCE

Dr. Dai’s cross-continental experience—from China to Germany—bridges Eastern and Western oncology practices. Her insights contribute to both clinical protocol improvements and space-radiation biology, collaborating with institutions such as the European Space Agency and Heidelberg Ion Beam Therapy Center. She plays a vital role in shaping translational cancer science and space medicine.

🏆ACADEMIC CITES, ACCOLADES AND RECOGNITION

  • Lead or corresponding author in high-impact journals: Cancer Letters (IF 9.7), APL Bioengineering (IF 6.6), and Frontiers in Oncology.

  • Honored with Outstanding Master’s Graduate award.

  • Latin honors “Magna Cum Laude” for doctoral studies in Germany.

  • Recognized as equal-first author and corresponding author in multiple prestigious publications.

🏆LEGACY AND FUTURE CONTRIBUTIONS

Dr. Dai is establishing a legacy of translational research at the intersection of radiation therapy, immunology, and biomarker discovery. Her future pursuits aim to:

  • Advance predictive markers for immunotherapy outcomes.

  • Explore MSC-based interventions against radiation-induced myelotoxicity.

  • Lead multinational clinical collaborations in cancer therapy and space radiation countermeasures.

🧬CONCLUSION

Dr. Ping Dai is an emerging force in molecular oncology and translational medicine. With a rich academic foundation, strong clinical acumen, and a forward-thinking research vision, she is contributing impactful solutions to global oncology and radiobiology challenges.

📊🔬NOTABLE PUBLICATION:

Thyroid dysfunction as a predictor of PD-1/PD-L1 inhibitor efficacy in advanced lung cancer

Authors: Yanling Wang, Xiaoping Ma, Jia Ma, Jing Li, Zhiyi Lin, Wei Gao, Ping Gong, Ping Dai
Journal: BMC Cancer
Year: 2025

Comprehensive Simulations of Intracellular Electric Fields during Exposure to Tumor Treating Fields (TTFields)

Authors: Kaida Liu, Ping Dai, Zirong Liu, Haohan Fang, Xing Li, Wei Gao
Journal: Frontiers in Oncology
Year: 2025 (Accepted)

Electrodynamic Interaction between Tumor Treating Fields and Microtubule Electrophysiological Activities

Authors: Xing Li, Kaida Liu, Haohan Fang, Zirong Liu, Yuchen Tang, Ping Dai
Journal: APL Bioengineering
Year: 2024

A theoretical study on evaluating brain tumor changes in tumor treating fields therapy by impedance detection

Authors: Xing Li, Kaida Liu, Haohan Fang, Rongzi Liu, Wei Gao, Ping Dai
Journal: Frontiers in Oncology
Year: 2024

Ohidul Alam | Cancer Science | Best Researcher Award

Posted on by Pencis

Dr. Ohidul Alam | Cancer Science | Best Researcher Award

Jiangsu University | China

AUTHOR PROFILE

GOOGLE SCHOLAR

ORCID ID

🏥DR. OHIDUL ALAM: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Ohidul Alam began his academic journey with a BSc (Hons.) in Environmental Science at the Institute of Forestry and Environmental Sciences, University of Chittagong, Bangladesh. He further completed his MS in Environmental Science at the same institute. His quest for global academic excellence led him to Tongji University, Shanghai, where he earned his MEng in Environmental Engineering, supported by the UNEP-Tongji Institute of Environment for Sustainable Development. He achieved his Ph.D. in Environmental Engineering from East China University of Science and Technology, focusing on sustainable materials and pollution control.

🩺PROFESSIONAL ENDEAVORS

Dr. Alam’s professional journey is marked by diverse roles across academia, consultancy, and environmental policy. He currently serves as a Post-doctoral Research Fellow at the School of the Environment and Safety Engineering, Jiangsu University, China, where he leads cutting-edge research on heavy metals, microplastics, and hazardous waste management.

Prior roles include:

  • Environmental Officer at the Sustainable Enterprise Project (SEP), Bangladesh

  • Consultant at DM WATCH (focusing on climate change and hazard risk management)

  • Manager at Aurora Consultant Limited

  • Research Assistant for GIZ, IUCN, and Japan-funded environmental and socio-economic projects

  • Guest Lecturer at Chattogram Polytechnic Institute

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON ENVIRONMENT

While Dr. Alam’s primary research is in environmental engineering and waste management, his work has strong implications for cancer science through the lens of public health and environmental carcinogen exposure. His investigation into heavy metals, microplastics, and pollutants directly aligns with cancer risk assessment, particularly regarding chronic exposure to hazardous waste, antibiotic resistance genes, and environmental toxins in water and soil.

His postdoctoral work, titled “Heavy Metals, Microplastics, and Waste Management: Environmental and Health Perspectives”, contributes to the understanding of environmental triggers in non-communicable diseases including cancer.

🌍IMPACT AND INFLUENCE

Dr. Alam has established himself as a globally engaged researcher, presenting in international conferences and contributing to policy-relevant research in South Asia and China. His work informs sustainable practices and evidence-based environmental governance.

  • Participated in leading workshops on Climate Change, LCA, and Solid Waste Management

  • Engaged with international initiatives under UNEP, USAID, and GIZ

  • Actively contributes to academic capacity building in Bangladesh and China

🔑 Keywords: International Collaboration, Environmental Policy, South Asia, Global Sustainability

📚 ACADEMIC CITATIONS, ACCOLADES, AND RECOGNITION

Dr. Alam has published over 31 peer-reviewed journal articles (16 SCI-indexed, 9 open-access international, 3 national journals, and 3 technical notes). Additionally, he has authored 13 international conference papers. He serves as a reviewer for respected journals such as:

  • Journal of Environmental Management

  • Environmental Research

  • Sustainable Cities and Society

🏆LEGACY AND FUTURE CONTRIBUTIONS

Dr. Alam’s research aims to bridge environmental engineering with health and sustainability, particularly focusing on pollution-derived health risks. He envisions developing green materials, safer waste disposal technologies, and cancer risk-reducing environmental frameworks. His mentorship of peers and support for junior researchers highlight his commitment to capacity building and knowledge sharing.

🧬CONCLUSION

Dr. Ohidul Alam stands as a multidisciplinary environmental researcher whose work integrates science, policy, and public health. His academic rigor, international exposure, and dedication to sustainable development make him a formidable contributor to environmental and health sciences, with growing relevance in the domain of environmental oncology and pollution-induced diseases.

📊🔬NOTABLE PUBLICATION:

Influences of chemically controlled Ca-bearing minerals in chitosan on Pb²⁺ removal efficiency

Author(s): Ohidul Alam, Xiuchen Qiao
Journal: Journal of Environmental Health Science and Engineering
Year: 2020

The effect of Ca-bearing contents in chitosan on Pb²⁺, Cd²⁺ and Cu²⁺ adsorption and its adsorption mechanism

Author(s): Ohidul Alam, Xiuchen Qiao, Tapan Kumar Nath
Journal: Journal of Environmental Health Science and Engineering
Year: 2020

A preliminary life cycle assessment on healthcare waste management in Chittagong City, Bangladesh

Author(s): Ohidul Alam, A. Mosharraf
Journal: International Journal of Environmental Science and Technology
Year: 2020

An in-depth review on municipal solid waste management, treatment and disposal in Bangladesh

Author(s): Ohidul Alam, Xiuchen Qiao
Journal: Sustainable Cities and Society
Year: 2020

Determination of the selected heavy metal and metalloid contents in various types of plastic bags

Author(s): Ohidul Alam, Li Yang, Xu Yanchun
Journal: Journal of Environmental Health Science and Engineering
Year: 2019